<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01401192</url>
  </required_header>
  <id_info>
    <org_study_id>2011-06-006</org_study_id>
    <nct_id>NCT01401192</nct_id>
  </id_info>
  <brief_title>Pemetrexed/Cisplatin Versus Gemcitabine/Cisplatin According to Thymidylate Synthase Expression</brief_title>
  <official_title>A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study trys to evaluate the predictive role of thymidylate synthase expression for
      pemetrexed/cisplatin in Non-small Cell Lung Cancer (NSCLC).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>predictive value of TS expression</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the predictive value of thymidylate synthase expression in NSCLC patients treated with pemetrexed combination therapy by interaction P value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Whether the response rate of CG regimen is higher than that of CP regimen in TS+ patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Whether the response rate of CP regimen is higher than that of CG regimen in TS- patients</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>TS positive cohort &amp; Gem/Cis Tx arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Among TS expression positive patients, some will be randomized to Gem/cis therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS+ cohort &amp; Pem/Cis arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Among patients with TS+, randomised to Pem/cis chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS negative cohort &amp; Pem/Cis Tx arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Among patients with TS-, some will be randomised to Pem/cis Tx arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS negative cohort &amp; Gem/Cis Tx arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Among patients with TS-, some will be randomised to Gem/Cis Tx arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus cisplatin</intervention_name>
    <description>Gemcitabine 1000mg/m2 D1, D8 &amp; cisplatin 70mg/m2 D1 every 3 weeks</description>
    <arm_group_label>TS positive cohort &amp; Gem/Cis Tx arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed plus cisplatin</intervention_name>
    <description>Pemetrexed 500mg/m2 &amp; cisplatin 70mg/m2 D1 every 3 weeks</description>
    <arm_group_label>TS+ cohort &amp; Pem/Cis arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed plus cisplatin</intervention_name>
    <description>pemetrexed 500mg/m2 &amp; cisplatin 70mg/m2 every 3 weeks</description>
    <arm_group_label>TS negative cohort &amp; Pem/Cis Tx arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus cisplatin</intervention_name>
    <description>Gemcitabine 1000mg/m2 D1, D8 &amp; cisplatin 70mg/m2 D1 every 3 weeks</description>
    <arm_group_label>TS negative cohort &amp; Gem/Cis Tx arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed nonsquamous NSCLC

          -  Stage IIIb, IV or recurrent NSCLC

          -  Age ≥ 18years

          -  ECOG performance status of 0 to 1

          -  Known TS immunohistochemical analysis data

          -  At least one measurable lesion by RECIST 1.1

          -  No previous chemotherapy or therapy with EGFR TKIs for advanced NSCLC

          -  Asymptomatic brain metastasis or symptomatic brain metastasis treated with local
             treatment such as operation, whole brain radiotherapy, or gamma-knife surgery

          -  At least 2 weeks later after whole brain radiotherapy or palliative radiotherapy

          -  Adequate renal function: estimated creatinine clearance ≥ 50mL/min

        Exclusion Criteria:

          -  Patients whose disease recurred within 6 months after the completion of adjuvant
             chemotherapy.

          -  Patients with post-obstructive pneumonia or uncontrolled serious infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung-Ju Ahn, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Myung-Ju Ahn, Pf</last_name>
    <phone>822-3410-3459</phone>
    <email>silkahn@skku.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-Ju Ahn, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jong-Mu Sun, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2011</study_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Myung-Ju Ahn, M.D., Ph.D.</name_title>
    <organization>Samsung medical center</organization>
  </responsible_party>
  <keyword>thymidylate synthase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

